Nivolumab-Ipilimumab


( Last Updated : December 18, 2020)
Generic Name:
nivolumab-ipilimumab
Project Status:
Active
Therapeutic Area:
Malignant Pleural Mesothelioma (MPM)
Manufacturer:
Bristol-Myers Squibb
Call for patient/clinician input open:
Brand Name:
Opdivo-Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0229-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open September 30, 2020
Call for patient/clinician input closed November 19, 2020
Clarification:

- Patient input submission received from Lung Cancer Canada

Submission received October 29, 2020
Submission accepted November 12, 2020
Review initiated November 13, 2020
Draft CADTH review report(s) provided to sponsor for comment February 25, 2021
Deadline for sponsors comments March 08, 2021
CADTH responses on draft review report(s) provided to sponsor April 05, 2021
Expert committee meeting (initial) April 15, 2021
Draft recommendation issued to sponsor June 07, 2021
Draft recommendation posted for stakeholder feedback June 17, 2021
End of feedback period July 02, 2021
Final recommendation issued to sponsor and drug plans July 16, 2021
Final recommendation posted August 04, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) July 30, 2021
CADTH review report(s) posted